Digest

This podcast explores various pre-exposure prophylaxis (PrEP) options for preventing HIV infection. It begins by introducing the New England Journal of Medicine's editorial fellowship program. The main focus is on comparing different PrEP methods, starting with daily oral pills like Truvada (TDF/FTC) and Descovy (TAF/FTC), discussing their mechanisms of action and efficacy in trials like iPrEX. The podcast then delves into on-demand PrEP and its adherence challenges. Long-acting injectable options like Cabenuva (cabotegravir) are examined, highlighting their advantages and disadvantages, including potential delays in HIV detection. A significant portion of the podcast is dedicated to the PURPOSE trials evaluating lenacapavir, a long-acting injectable capsid inhibitor. The remarkable effectiveness of lenacapavir, particularly in populations with poor adherence to oral PrEP, is discussed, along with its potential to revolutionize HIV prevention. The podcast concludes by addressing remaining challenges in HIV prevention, such as drug resistance, equitable access, and the importance of continued advocacy and policy changes to ensure widespread availability and effectiveness of PrEP. The crucial distinction between efficacy (ideal conditions) and effectiveness (real-world use) is emphasized throughout.

Outlines

00:00:00

HIV Prevention: PrEP Options and the PURPOSE Trials

This podcast introduces the NEJM editorial fellowship and then comprehensively reviews various HIV PrEP options, including oral medications (Truvada, Descovy) and long-acting injectables (Cabenuva, lenacapavir), focusing on their mechanisms, efficacy, effectiveness, and adherence challenges. The groundbreaking results of the PURPOSE trials evaluating lenacapavir are highlighted.

00:01:24

Mechanism of PrEP and Early Trials

This section details the challenges of HIV treatment, explains the mechanism of PrEP (specifically Truvada), its efficacy in the iPrEX trial, and the impact of adherence on effectiveness. It also introduces Descovy as an alternative and discusses on-demand PrEP.

00:13:07

Long-Acting PrEP and Future Directions

This section covers long-acting injectable PrEP options like Cabenuva and lenacapavir, comparing their efficacy to oral PrEP. It summarizes the findings of the PURPOSE trials, emphasizing lenacapavir's effectiveness, especially in populations with low adherence. Finally, it discusses challenges and future directions in HIV prevention, including drug resistance, equitable access, and the need for continued advocacy.

Keywords

Q&A

• What are the main differences between Truvada, Descovy, and Cabenuva as PrEP options?

  Truvada and Descovy are daily oral pills; Cabenuva is a long-acting injectable. They differ in their nucleoside reverse transcriptase inhibitors; Cabenuva offers improved adherence but may delay HIV detection.

• What were the key findings of the PURPOSE trials regarding lenacapavir?

  PURPOSE 1 showed zero HIV infections in cisgender women in sub-Saharan Africa using lenacapavir; PURPOSE 2 demonstrated high efficacy in MSM and transgender women. Long-acting nature improved adherence.

• What are the major challenges in ensuring widespread access to effective PrEP?

  High cost, stigma, adherence issues, healthcare infrastructure, and policy changes are major barriers to widespread access.

• How does efficacy versus effectiveness relate to PrEP?

  PrEP's high efficacy in trials contrasts with lower real-world effectiveness due to adherence issues; long-acting injectables aim to improve this.

• What are the potential downsides of long-acting injectable PrEP like lenacapavir?

  Delayed HIV diagnosis, potential drug resistance (though rare), and injection site reactions are potential downsides.

Show Notes